Orca Bio

Orca T Account Manager (OTAM) - East / Central / West

Remote

Not SpecifiedCompensation
Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

Candidates must possess a Bachelor's degree (BA/BS) and ideally an advanced degree in a scientific or business field. A minimum of 8-10 years of experience in the healthcare, biotech, or pharmaceutical industry, with a preference for cell therapy experience, is required. A proven track record in account management, particularly in oncology, hematology, or cell therapy, is essential, along with a strong operational understanding of academic medical centers or transplant centers. Preferred qualifications include an MBA or related advanced degree, 5+ years of experience in hematology/oncology or bone marrow transplantation, prior experience launching or supporting cell or gene therapy products, familiarity with site operations, patient access pathways, and clinical treatment logistics, and previous experience working in cross-functional field-based teams. Willingness to travel up to 50% is also a requirement.

Responsibilities

The Orca T Account Manager (OTAM) will act as the primary liaison between Orca Bio and Authorized Treatment Centers (ATCs), building and managing key relationships with decision-makers and stakeholders. Responsibilities include supporting clinical site readiness and execution, driving appropriate use of Orca Bio’s investigational therapies, and ensuring a smooth and effective experience for clinical sites, physicians, and other healthcare stakeholders. This involves leading site onboarding activities, serving as the on-the-ground expert for logistics and operational readiness, and overseeing product handling, including Chain of Identity (COI) and Chain of Custody (COC) compliance. The OTAM will also educate site personnel on therapies and clinical data, work closely with cross-functional teams to resolve barriers, and facilitate communication of updates. Additionally, they will analyze account performance, identify opportunities to optimize site engagement and therapy utilization, gather and share market insights, and represent Orca Bio at key conferences.

Skills

Relationship Management
Clinical Site Readiness
Logistics
Operational Readiness
Strategic Planning
Stakeholder Engagement
Biotechnology
Cell Therapy

Orca Bio

Develops and commercializes cell therapies

About Orca Bio

Orca Bio operates in the biotechnology sector, specifically focusing on cell therapies that utilize the body's own cells to treat diseases. The company works to enhance these therapies, aiming to make them safer and more effective for patients. Orca Bio's products are primarily used by healthcare providers who administer these therapies to patients as part of their treatment plans. Unlike many competitors, Orca Bio emphasizes a strong team culture and values communication with stakeholders, keeping them informed about the company's progress and developments. The goal of Orca Bio is to improve patient outcomes through advanced cell therapies, addressing conditions that currently have limited treatment options.

Menlo Park, CaliforniaHeadquarters
2016Year Founded
$186.8MTotal Funding
SERIES_DCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Unlimited Paid Time Off
401(k) Retirement Plan
Parental Leave

Risks

Emerging competition from BlueRock Therapeutics in stem cell therapies.
Aspen Neuroscience's advancements in personalized stem cell therapies pose a threat.
Competitors' focus on iPSC-derived therapies may overshadow Orca Bio's offerings.

Differentiation

Orca Bio focuses on high-precision cell therapies for cancer and autoimmune diseases.
Their lead product, Orca-T, shows promising relapse-free survival rates in clinical trials.
Orca Bio's therapies aim to replace diseased blood and immune systems with healthy ones.

Upsides

Orca-T demonstrated 87% relapse-free survival in a Phase 1b/2 trial.
FDA's expedited approval pathways could accelerate Orca Bio's market entry.
Advancements in gene editing enhance the efficacy of Orca Bio's cell therapies.

Land your dream remote job 3x faster with AI